Literature DB >> 20445161

Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.

Baptist Trimbos1, Petra Timmers, Sergio Pecorelli, Corneel Coens, Koen Ven, Maria van der Burg, Antonio Casado.   

Abstract

A long-term follow-up analysis of the randomized clinical trial Adjuvant Chemotherapy in Ovarian Neoplasm (ACTION) from the European Organization for Research and Treatment of Cancer was undertaken to determine whether the original results with a median follow-up of 5.5 years could be verified after longer follow-up with more events. In the ACTION trial, 448 patients with early ovarian cancer were randomly assigned, after surgery, to adjuvant chemotherapy or to observation (no further treatment). The original analysis found that adjuvant chemotherapy improved recurrence-free survival but not overall survival and found in a subgroup analysis that completeness of surgical staging was an independent prognostic factor, with better recurrence-free and overall survival among those with complete (optimal) surgical staging. After a median follow-up of 10.1 years, we analyzed the more mature data from the ACTION trial and found support for most of the main conclusions of the original analysis, except that overall survival after optimal surgical staging was improved, even among patients who received adjuvant chemotherapy (hazard ratio of death = 1.89, 95% confidence interval = 0.99 to 3.60; overall two-sided log-rank test P = .05). More cancer-specific deaths were observed among nonoptimally staged patients (40 [27%] of the 147 deaths in the observation arm and 11 [14%] of the 76 deaths in the adjuvant chemotherapy arm) than among optimally staged patients (seven [9%] of the 75 deaths in the observation arm and 11 [14%] of the 76 deaths in the adjuvant chemotherapy arm) (two-sided chi(2) test for heterogeneity, P = .06). Thus, completeness of surgical staging in patients with early ovarian cancer was found to be statistically significantly associated with better outcomes, and the benefit from adjuvant chemotherapy appeared to be restricted to patients with nonoptimal surgical staging.

Entities:  

Mesh:

Year:  2010        PMID: 20445161      PMCID: PMC2911043          DOI: 10.1093/jnci/djq149

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

Authors:  I Vergote; J De Brabanter; A Fyles; K Bertelsen; N Einhorn; P Sevelda; M E Gore; J Kaern; H Verrelst; K Sjövall; D Timmerman; J Vandewalle; M Van Gramberen; C G Tropé
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

Review 2.  Chemotherapy for early ovarian cancer.

Authors:  J Baptist Trimbos; Petra Timmers
Journal:  Curr Opin Obstet Gynecol       Date:  2004-02       Impact factor: 1.927

Review 3.  Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.

Authors:  Claes Tropé; Janne Kaern
Journal:  J Clin Oncol       Date:  2007-07-10       Impact factor: 44.544

4.  Second malignant neoplasms among long-term survivors of ovarian cancer.

Authors:  L B Travis; R E Curtis; J D Boice; C E Platz; B F Hankey; J F Fraumeni
Journal:  Cancer Res       Date:  1996-04-01       Impact factor: 12.701

5.  Staging laparotomy in early ovarian cancer.

Authors:  R C Young; D G Decker; J T Wharton; M S Piver; W F Sindelar; B K Edwards; J P Smith
Journal:  JAMA       Date:  1983-12-09       Impact factor: 56.272

6.  Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

Authors:  J Baptist Trimbos; Ignace Vergote; Giorgio Bolis; Jan B Vermorken; Constantino Mangioni; Caterina Madronal; Massimo Franchi; Saverio Tateo; Gerardo Zanetta; Giovanna Scarfone; Livia Giurgea; Petra Timmers; Corneel Coens; Sergio Pecorelli
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

Review 7.  Treatment of patients with early epithelial ovarian cancer.

Authors:  Ignace Vergote; Baptist J Trimbos
Journal:  Curr Opin Oncol       Date:  2003-11       Impact factor: 3.645

  7 in total
  23 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

2.  If the Mountain Does Not Come to Mohammad: The Significance of Guest Operations for Early Stage Ovarian Cancer.

Authors:  Inge T A Peters; Carolien van Haaften; J Baptist Trimbos
Journal:  J Gynecol Surg       Date:  2014-10-01

3.  Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.

Authors:  Helen E Dinkelspiel; Ana I Tergas; Lilli A Zimmerman; William M Burke; June Y Hou; Ling Chen; Grace Hillyer; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2015-02-20       Impact factor: 5.482

Review 4.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Authors:  Brett A Winter-Roach; Henry C Kitchener; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

5.  [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].

Authors:  H Löser; C Heydt; R Büttner; B Markiefka
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

Review 6.  Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.

Authors:  Nithya D G Ratnavelu; Andrew P Brown; Susan Mallett; Rob J P M Scholten; Amit Patel; Christina Founta; Khadra Galaal; Paul Cross; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2016-03-01

Review 7.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Authors:  Theresa A Lawrie; Brett A Winter-Roach; Pauline Heus; Henry C Kitchener
Journal:  Cochrane Database Syst Rev       Date:  2015-12-17

8.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

9.  GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.

Authors:  A González Martín; A Redondo; M Jurado; A De Juan; I Romero; I Bover; J M Del Campo; A Cervantes; Y García; J A López-Guerrero; C Mendiola; J Palacios; M J Rubio; A Poveda Velasco
Journal:  Clin Transl Oncol       Date:  2013-03-07       Impact factor: 3.405

10.  Genomic aberrations relate early and advanced stage ovarian cancer.

Authors:  Afra Zaal; Wouter J Peyrot; P M J J Berns; Maria E L van der Burg; Jan H W Veerbeek; J Baptist Trimbos; Isabelle Cadron; Paul J van Diest; Wessel N van Wieringen; Oscar Krijgsman; Gerrit A Meijer; Jurgen M J Piek; Petra J Timmers; Ignace Vergote; René H M Verheijen; Bauke Ylstra; Ronald P Zweemer
Journal:  Cell Oncol (Dordr)       Date:  2012-05-12       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.